You searched for:"Francisco José Candido dos Reis"
We found (23) results for your search.Summary
Rev Bras Ginecol Obstet. 2006;28(1):1-2
Summary
Rev Bras Ginecol Obstet. 1998;20(2):118-118
DOI 10.1590/S0100-72031998000200011
Summary
Rev Bras Ginecol Obstet. 2007;29(4):181-185
DOI 10.1590/S0100-72032007000400003
PURPOSE: to determine the efficacy of 10% lidocaine spray applied to the cervix before the procedure of diagnostic hysteroscopy, in order to reduce the painful process and the discomfort caused by the exam. METHODS: a total of 261 consecutive patients participated in the study, which was conducted from March 2004 to March 2005. The patients were randomly assigned to one of two groups: one group receiving topical lidocaine spray (lidocaine group - LdG) and the other, receiving no medication before the procedure (control group - CG). In the LdG patients, thirty milligrams of 10% lidocaine spray were applied to the surface of the cervix five minutes before hysteroscopy started. Immediately, after the end of the procedure, the patients from both groups were asked to respond to a questionnaire about pain and to quantify the pain, in centimeters, using a 10-cm non-graduated visual analog scale. The unpaired t test, the Mann-Whitney test and the chi2 test were used for statistical analyses, considering p significant if lower than 0.05. RESULTS: there was no statistically significant difference between groups regarding age, parity or percentage of patients in menacme or menopause, or regarding the indications for the procedure and the hysteroscopic findings. A biopsy was necessary in 57 of the 132 LdG patients and in 48 of the 129 CG patients (p=0.96). The mean pain score was 4.3±2.9 in LdG and 3.9±2.5 in CG (p=0.2). A difference in the mean pain score was observed only among patients in menacme and menopause receiving or not the lidocaine spray, with p=0.01 and p=0.04 respectively. CONCLUSIONS: the use of lidocaine spray during diagnostic hysteroscopy does not minimize the discomfort and pain of the patients and therefore should not be applied.
Summary
Rev Bras Ginecol Obstet. 1998;20(4):209-213
DOI 10.1590/S0100-72031998000400006
Fine-needle aspiration cytology (FNAC) is a simple method and free from complications, among great value in mastology. Its accuracy can suffer the influence of several factors, among which we can highlight the experience of the physician who performs it. With the objective of verifying the effectiveness of FNAC performed by general gynecologists, 341 patients were studied concerning the relationship between the results of FNAC and the histology of the breast lesion. We obtained sensitivity of 70.87%, specificity of 70.58%, predictive positive value of 92.40%, predictive negative value of 89.36% and accuracy of 70.67%. We concluded that FNAC is of great value in handling breast lesions and can be appropriately performed by general gynecologists. The method, however, may lead to errors of diagnosis. We do not recommend, therefore, the use of the result of FNAC as a definitive diagnosis; instead this result must be interpreted in the context of the clinical diagnosis and mammography.
Summary
Rev Bras Ginecol Obstet. 2004;26(3):227-232
DOI 10.1590/S0100-72032004000300009
PURPOSE: to identify the risk factors associated with the occurrence of surgical site infection (SSI) in surgeries for the treatment of breast cancer. METHODS: the study was conducted on 140 women submitted to treatment of invasive breast cancer during the period from January 2001 to December 2002. SSI was defined as infection occurring up to 30 days after surgery and was related to the operation, according to the standard criteria adopted by the Centers for Disease Control and Prevention (CDC), USA. SSI were considered to be superficial when they involved only the skin and subcutaneous tissue and deep when they involved deep tissues at the site of incision, such as fascia and muscles. The risk factors related to patient were age, hormonal status, staging, body mass index (BMI) and hemoglobin, and the factors related to surgery were type of operation, time of hospitalization, duration of surgery, and formation of seroma and hematoma. Data concerning numerical nonparametric variables were analyzed by the Mann-Whitney test and quantitative variables were analyzed by the Fisher exact test. RESULTS: of the 140 patients studied, 29 (20.7%) presented SSI, which were superficial in 19 (13.6%) and deep in 10 (71%); 111 patients did not present SSI and represented the control group. The risk factors associated with the patient and the disease were locally advanced stage (odds ratio = 27; 95% CI: 1.1-6.5) and obesity, represented by a mean BMI of 32.2 kg/m² in the patients with SSI and a mean BMI of 27.2 kg/m² in the control group (p<0.0001). The factors related to treatment of the disease were the use of neoadjuvant chemotherapy (odds ratio = 2.7 (95% CI: 1.1-6.5), the duration of surgery, whose median value was 165 minutes for the patients who developed the infection and 137 minutes for the control group (p=0.02), and the number of days of use of the postoperative drain, whose median value was 6 days for the patients with SSI and 5 days for the control group (p=0.048). CONCLUSION: on the basis of the identification of risk factors such as advanced stage, neoadjuvant chemotherapy and obesity, preoperative care for these patients should be emphasized. The use of an accurate surgical technique may reduce the impact of other factors such as surgical time and time of use of the drain.
Summary
Rev Bras Ginecol Obstet. 2004;26(3):253-253
Summary
Rev Bras Ginecol Obstet. 2005;27(6):331-339
DOI 10.1590/S0100-72032005000600007
PURPOSE: to evaluate the epidemiologic data and signs of trophoblastic hyperplasia in patients with complete hydatidiform mole (CHM) and to estimate the risk associated with the persistence of the disease. METHODS:: we evaluated 214 patients with CHM submitted to uterine evacuation between 1980 and 2001. The patients were included prospectively. All patients were followed until negative bHCG with weekly clinical evaluation and bHCG quantification. We considered persistence when the patient needed another treatment after uterine evacuation. The risk factors for persistence were evaluated through univariate and multivariate analysis, and the odds ratio (OR) was calculated for each one. RESULTS: among the epidemiologic factors, only negative Rh was significant (OR=2.28). All signs of trophoblastic hyperplasia, represented by uterine size larger than expected, sonographic uterine volume, tecaluteinic cysts, and betaHCG higher than 10(5) were associated with risk for the presistence of the disease. The presence of at least one sign of trophoblastic hyperplasia showed sensitivity of 82% and predictive positive value of 35.1% (OR=4.8). The logistic regression identified larger uterine size than expected and bHCG higher than 10(5) as risk factors for persistence of the gestational trophoblastic disease (OR=4.1 and 5.5, respectively). CONCLUSIONS: the signs of trophoblastic hyperplasia showed good sensitivity to predict persistence of the disease; however, the low predictive positive value does not allow using these criteria to change treatment. It is very important to reinforce the importance of serial betaHCG quantification in these high-risk patients.